Personalized ESA Dosing via PK/PD Modeling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for anemia in cancer patients, particularly those with non-small cell lung carcinoma, face challenges due to variability in responses to Erythropoiesis Stimulating Agents (ESAs), with 30-40% of patients not responding effectively and concerns over tumor progression and mortality risks, necessitating optimized dosage regimens to avoid over- or under-dosing.

Innovation Solution

A method using a non-linear dynamic pharmacokinetic (PK) hemoglobin (Hb) ESA-EPO-R pathway model to calculate individual ESA dosages based on patient-specific hemoglobin degradation rates and binding properties, ensuring optimal ESA administration and minimizing risks of thrombovascular events.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If fixed dosage regimens of ESA are used for treating anemia in cancer patients, then treatment simplicity is maintained, but treatment effectiveness deteriorates due to high variability in patient responses (30-40% non-responders)

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddosage regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by determining individual patient-specific parameters (ESA binding sites, hemoglobin degradation rate) to customize the dosage regimen. Instead of using fixed dosages, the method calculates optimized ESA doses based on each patient's unique pharmacokinetic and pharmacodynamic characteristics, thereby improving treatment effectiveness while managing complexity through standardized measurement protocols

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements feedback mechanisms by measuring patient response to ESA treatment (hemoglobin levels, ESA binding site occupancy) and using this information to adjust subsequent dosing. The method incorporates monitoring of treatment effectiveness and uses this feedback to refine dosage recommendations, ensuring optimal therapy while adapting to individual patient responses

Inventive Principle:

Principle #23Feedback

2Reliability

If higher ESA dosages are administered to ensure adequate hemoglobin levels, then anemia treatment effectiveness improves, but the risk of harmful effects increases (thrombovascular events, tumor progression)

Engineering Contradiction:

Improveanemia treatment effectivenessVSAvoidthrombovascular events and tumor progression risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses parameter changes to determine the minimum effective ESA dosage by calculating patient-specific parameters including hemoglobin degradation rate and ESA binding site occupancy. This approach identifies the lowest dosage that achieves adequate hemoglobin levels, avoiding excessive dosing that would increase thrombovascular and tumor progression risks

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces empirical dosage determination with a quantitative pharmacokinetic/pharmacodynamic modeling approach. By using mathematical models to predict ESA behavior and patient response, the method substitutes trial-and-error dosing with calculated optimal dosages, thereby minimizing harmful effects while maintaining treatment effectiveness

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If personalized dosage calculation methods are implemented, then treatment precision improves, but measurement and calculation complexity increases

Engineering Contradiction:

Improvedosage determination precisionVSAvoidmeasurement and calculation complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent determines patient-specific parameters (ESA binding sites, hemoglobin degradation rate, ESA clearance rate) that enable precise dosage calculation. By measuring these specific parameters through standardized assays and incorporating them into pharmacokinetic/pharmacodynamic models, the method achieves high dosage determination precision

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces pharmacokinetic/pharmacodynamic modeling as an intermediary between raw measurement data and final dosage recommendations. The models process measured parameters (binding site occupancy, hemoglobin levels) and translate them into optimized dosage regimens, managing calculation complexity while maintaining precision

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP3157545B1Methods for the prediction of a personalized ESA-dose in the treatment of anemia

Publication Date: 2023.08.09 DEUTES KREBSFORSCHUNGSZENT STIFTUNG DES OFFENTLICHEN RECHTS

Figure 1a
Figure 1b
Figure 1c

AI summary

The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.